MedTrace Logo

REduction of rIsk for Contrast Induced Nephropathy

NCT01402232 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2018-08-03

No results posted yet for this study

Summary

The REduction of rIsk for Contrast-Induced Nephropathy (REICIN) study is the largest prospective multicenter data base for CIN flowing coronary angiography (CAG) or percutaneous coronary intervention (PCI). The REICIN study has the potential to characterize contemporary CIN incidence, modified risk factors and prognosis, so that to identify strategiaes to reduce risk of CIN following CAG/PCI.

Conditions

  • Contrast Induced Nephropathy

Sponsors & Collaborators

  • First Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    collaborator OTHER

  • Nanfang Hospital, Southern Medical University

    collaborator OTHER

  • Guangzhou General Hospital of Guangzhou Military Command

    collaborator OTHER

  • Guangdong Medical College

    collaborator OTHER

  • Dongguan Kanghua Hospital

    collaborator OTHER

  • Dongguan People's Hospital

    collaborator OTHER_GOV

  • Maoming People's Hospital

    collaborator OTHER

  • Futian People's Hospital

    collaborator OTHER

  • Longyan City First Hospital

    collaborator OTHER

  • First People's Hospital of Kashgar

    collaborator UNKNOWN

  • Guangdong Provincial People's Hospital

    lead OTHER

Principal Investigators

  • Yong Liu, MD,PhD · Guangdong Cardiovascular Institute,Guangdong General Hospital

  • Shiqun Chen, MS · Guangdong Cardiovascular Institute,Guangdong General Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2016-02-29
Completion
2018-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01402232 on ClinicalTrials.gov